Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H29FN2O2 |
Molecular Weight | 348.4549 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1CCN(CCCN2C(=O)COC3=CC(F)=CC=C23)CC1
InChI
InChIKey=BWAKMLKESHKOHK-UHFFFAOYSA-N
InChI=1S/C20H29FN2O2/c1-2-3-5-16-8-12-22(13-9-16)10-4-11-23-18-7-6-17(21)14-19(18)25-15-20(23)24/h6-7,14,16H,2-5,8-13,15H2,1H3
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one) is a selective muscarinic M1 receptor agonist. The muscarinic M1 receptor agonist property of AC260584 contributes to its enhancement of cortical acetylcholine and dopamine efflux. In animal studies AC-260584 has a behavioral profile consistent with antipsychotic-like efficacy with the potential to improve cognitive performance and shows reduced liability for extrapyramidal symptoms.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19951444 |
7.6 null [pEC50] | ||
Target ID: CHEMBL276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16959945 |
7.8 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. | 2007 Oct 31 |
|
Confocal Analysis of Cholinergic and Dopaminergic Inputs onto Pyramidal Cells in the Prefrontal Cortex of Rodents. | 2010 |
|
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. | 2010 Feb |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17628522
Using microdialysis in awake, freely moving rats, AC260584, 3 and 10, but not 1 mg/kg (s.c.), significantly increased dopamine release in the medial prefrontal cortex and hippocampus. However, only the high dose of AC260584, 10 mg/kg (s.c.), significantly increased acetylcholine release in these regions.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19491322
Local perfusion of rat medial prefrontal cortex with AC260584 (10-500 uM) significantly increased dopamine efflux.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9928284
Created by
admin on Sat Dec 16 08:09:24 GMT 2023 , Edited by admin on Sat Dec 16 08:09:24 GMT 2023
|
PRIMARY | |||
|
M4PN46N313
Created by
admin on Sat Dec 16 08:09:24 GMT 2023 , Edited by admin on Sat Dec 16 08:09:24 GMT 2023
|
PRIMARY | |||
|
560083-42-3
Created by
admin on Sat Dec 16 08:09:24 GMT 2023 , Edited by admin on Sat Dec 16 08:09:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY